Advertisement

Topics

TNF-Kinoid - Biotech, Pharma and Life Science Channel

02:09 EST 17th November 2018 | BioPortfolio

Therapies targeting TNF have already demonstrated efficacy across a wide range of inflammatory diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondulitis, psoriasis and Crohn’s disease. The target market for Kinoids currently in development is estimated at over $24 billion, with potential to reach still broader markets (Source: LaMerie 2012).

Although powerful, current anti-TNFα therapies also have significant drawbacks, making new treatment approaches sorely needed. The most problematic aspect of monoclonal antibody (mAb) therapies is the frequent development of treatment resistance as they are used long-term to treat chronic diseases. For instance in Crohn’s disease, there is loss of response to monoclonal anti-TNF treatment in nearly 60% of patients (infliximab, adalimumab, certolizumab) during the first year of treament. Anti-TNFα treatments also have a cumbersome dosing regimen of frequent IV infusions or SC injections.

The TNF-Kinoid is a promising approach to address the shortcomings of the monoclonal antibodies.

Source: http://www.neovacs.fr/en/products/TNF-Kinoide

News Articles [7 Associated News Articles listed on BioPortfolio]

Neovacs announces in vivo Proof of Concept success for its IL-4 / IL-13 Kinoid a new Therapeutic Vaccine to treat Mite-induced Asthma

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs announces in vivo Proof of Concept success for its IL-4 / IL-13 Kinoid a new Therapeutic Vaccine to treat Mite-induced Asthma ...

Neovacs SA ALNEV Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 16102018] Prices from USD $250

SummaryNeovacs SA Neovacs is a biotechnology company that develops various therapeutic vaccines for the treatment of autoimmune disorders, inflammatory diseases and cancers. The company offers TNF kin...

KOL Perspectives: MidtoLate Stage Pipeline Therapies in Lupus [Report Updated: 01022018] Prices from USD $2500

KOL Perspectives: MidtoLate Stage Pipeline Therapies in LupusSummaryThis KOL Insight briefing focuses on opinions of mid to latestage pipeline therapies in lupus.The briefing includes analysis of KOL ...

NEOVACS ANNOUNCES THAT ITS PARTNER BIOSENSE GLOBAL HAS EXERCISED ITS OPTION TO ACQUIRE THE EXCLUSIVE LICENCE FOR IFNalpha KINOID TO TREAT LUPUS IN CHINA

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE  NEOVACS ANNOUNCES THAT ITS PARTNER BIOSENSE GLOBAL HAS EXERCISED ITS OPTION TO ACQUIRE THE EXCLUSIVE LICENCE FOR IFNalpha KINOID TO...

Neovacs SA ALNEV Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23042018] Prices from USD $250

SummaryNeovacs SA Neovacs is a biotechnology company which develops various therapeutic vaccines for autoimmune disorders, inflammatory diseases and cancers. The company offers TNF kinoid and IFNa kin...

NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR IFNalpha KINOID IN THE TREATMENT OF LUPUS

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES THE RESULTS OF ITS PHASE IIB STUDY FOR IFNalpha KINOID IN THE TREATMENT OF LUPUS WHICH ALLOWS TO PROCEED WITH THE CL...

NEOVACS STRENGTHENS INTELLECTUAL PROPERTY POSITION IN EUROPE AND JAPAN

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS STRENGTHENS INTELLECTUAL PROPERTY POSITION  IN EUROPE AND JAPAN Newly issued patent covers IFNalpha Kinoid and its application...

Events [0 Results]

None

Companies [0 Results]

None

Clinical Trials [5 Associated Clinical Trials listed on BioPortfolio]

Study of IFN-K in Dermatomyositis

This study is a Proof of Concept study aiming to evaluate the production of anti-IFNα antibodies (immune response) in adult subjects with dermatomyositis

Study of IFN-K in Systemic Lupus Erythematosus

The safety and immunogenicity of the IFN-Kinoid (IFN-K) have been evaluated in a phase I clinical study conducted in subjects with SLE. Preliminary results were promising. The principal a...

Immunogenicity and Safety of TNFa Kinoid in Rheumatoid Arthritis With Secondary Resistance to TNFa Antagonists and ADA

The objective of this trial is to demonstrate that active immunization with anti-TNFα kinoid (TNF-K) is able to induce polyclonal anti-TNFα antibodies in RA patients who were previously ...

Safety of IFNa Kinoid in Systemic Lupus Erythematosus

Interferon alpha (IFNa) is involved in the pathogenesis of systemic lupus erythematosus (SLE)and IFNa levels are associated with the severity of the disease. Blocking IFNa could be an attr...

Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease

Evaluation of the safety and the immune response induced by active immunization through a TNFa kinoid in patients with Crohn's disease.

PubMed Articles [0 Results]

None

Videos

None available.

Medical and Biotech [MESH] Definitions

None available.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cytokine Tumour Necrosis Factor (TNF)
TNF is a compound that is classified as a cytokine which plays a central role in the cellular mechanisms of apoptosis or cell death. However, there are a number of different kinds of TNF, just under twenty, but the family of molecules have very similar a...

Orthopedics
Arthroplasty Joint Disorders Orthopedics Spinal Cord Disorders Orthopedics is the science or practice of correcting deformities caused by disease or damage to the bones and joints of the skeleton. This specialized branch of surgery may ...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

review and buy TNF-Kinoid market research data and corporate reports here

Channels Quicklinks